SIGA BioArmor CEO Phil Gomez discusses the effectiveness of his company’s treatment against monkeypox, and how economic disparity stands in the way of providing dosages to vulnerable African nations. Segment originally aired on July 29, 2022.
PHIL GOMEZ: Monkeypox is different. It's a DNA virus. It's typically very stable over time. It's not an RNA virus, like influenza or coronavirus. So we're fortunate that as we saw with smallpox eradication, there was one vaccine. It was used very effectively to ultimately eradicate the disease.
So our drug is approved by the US FDA for the treatment of smallpox. It's not approved for the treatment of monkeypox, but I'd be happy to give you background because it's approved in Europe and the United Kingdom for the treatment of monkeypox and smallpox.
A case anywhere can be a case everywhere. So I think it would be very helpful to raise awareness in the public about the disease. We know this is going to get into additional populations. We knew early on a number of years ago with our approval, that monkeypox unfortunately, has become very endemic in Africa. And as a globe, we need to work very hard on making sure we have equitable access to drugs and vaccines.